ERBB2 and breast cancer: Traditionally, most experts recommended chemotherapy in patients with luminal BC and 4 or more positive nodes.7 More recently, genomic assays, such as the Oncotype DX Recurrence Score (Exact Sciences) or Mammaprint (Agendia), became available to refine chemotherapy indications in node-positive, HR-positive, ERBB2-negative BC.8,9 Because patients with more than 3 positive nodes were ineligible for these trials, applicability of their results to patients who did not undergo ALND remains questionable.